Overview of Systematic Reviews of Non–Vitamin K Oral Anticoagulants in Atrial Fibrillation
نویسندگان
چکیده
منابع مشابه
Non-vitamin K oral anticoagulants in atrial fibrillation
Atrial fibrillation (AF) confers increased risk of stroke and other thromboembolic events, and oral anticoagulation therefore is the essential part of AF management to reduce the risk of this complication. Until recently, the vitamin K antagonists (VKAs, e.g. warfarin) were the only oral anticoagulants available, acting by decreased synthesis of vitamin K-dependent coagulation factors (II, VI, ...
متن کاملNon-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
For more than 50 years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved for prevention of thromboembolism in patients with nonvalvular AF. This article provides an overview of AF, summarizes basi...
متن کاملPractical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants.
OBJECTIVES Dabigatran, rivaroxaban, apixaban, and edoxaban are nonvitamin K antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Phase-3 clinical trials demonstrated NOACs were as effective as warfarin in the prevention of stroke or systemic embolism and associated with decreased incidences of intracranial bleeding. Addit...
متن کاملPractical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants
Objectives: Dabigatran, rivaroxaban, apixaban, and edoxaban are nonvitamin K antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Phase-3 clinical trials demonstrated NOACs were as effective as warfarin in the prevention of stroke or systemic embolism and associated with decreased incidences of intracranial bleeding. Addi...
متن کاملNew oral anticoagulants in atrial fibrillation forever?
A trial fibrillation is the most common chronic cardiac arrhythmia in clinical cardiology. It affects ≈1% of the population, and, of individuals >80 years of age, ≈10% have this rhythm disturbance. Owing to the loss of the atrial contribution to ventricular filling, left ventricular function is diminished resulting in a propensity to heart failure, fatigue, and disability. Furthermore, the sens...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation: Cardiovascular Quality and Outcomes
سال: 2018
ISSN: 1941-7713,1941-7705
DOI: 10.1161/circoutcomes.118.004769